• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丝裂霉素、异环磷酰胺及美司钠治疗肺癌

Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.

作者信息

Dorr R T

机构信息

Arizona Cancer Center, University of Arizona College of Medicine, Tucson.

出版信息

Semin Oncol. 1990 Aug;17(4 Suppl 7):2-5.

PMID:2116668
Abstract

Observations have been made of the multiple-drug resistance phenomenon in mitomycin-exposed cells in vitro. Collateral resistance to anthracyclines and Vinca alkaloids was demonstrated in mitomycin carbon-treated 1-1210 cells in vitro. However, because it has also been found that this resistance can be reversed with agents such as verapamil and progestogens, it may be possible to effect a similar reversal in vivo. A study is currently being performed in patients with colorectal cancer, in which the potential for reversal is being tested. The pharmacokinetics of ifosfamide result in high cytotoxic specificity which, along with its therapeutic range, makes it a particularly active agent in the treatment of non-small cell lung cancer. Its urotoxicity is effectively controlled by the coadministration of mesna, a uroprotective agent.

摘要

已对体外丝裂霉素处理的细胞中的多药耐药现象进行了观察。体外实验表明,丝裂霉素C处理的1-1210细胞对蒽环类药物和长春花生物碱存在交叉耐药性。然而,由于还发现这种耐药性可用维拉帕米和孕激素等药物逆转,因此有可能在体内实现类似的逆转。目前正在对结直肠癌患者进行一项研究,以测试逆转的可能性。异环磷酰胺的药代动力学导致其具有高细胞毒性特异性,连同其治疗范围,使其成为治疗非小细胞肺癌的一种特别有效的药物。其尿路毒性可通过同时给予尿路保护剂美司钠有效控制。

相似文献

1
Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.丝裂霉素、异环磷酰胺及美司钠治疗肺癌
Semin Oncol. 1990 Aug;17(4 Suppl 7):2-5.
2
Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer.异环磷酰胺、丝裂霉素和顺铂联合化疗用于晚期非小细胞肺癌
Cancer Treat Rep. 1987 Sep;71(9):851-3.
3
An ongoing randomized study of neoadjuvant chemotherapy in resectable non-small cell lung cancer.
Semin Oncol. 1994 Jun;21(3 Suppl 4):16-9.
4
Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.阿霉素、异环磷酰胺和美司钠联合化疗治疗广泛期非小细胞支气管肺癌
Cancer Treat Rev. 1983 Sep;10 Suppl A:121-3. doi: 10.1016/s0305-7372(83)80016-4.
5
[Polychemotherapy of non-small cell bronchial cancer with mitomycin C, ifosfamide and vindesine].[丝裂霉素C、异环磷酰胺和长春地辛用于非小细胞支气管癌的联合化疗]
Pneumologie. 1990 Feb;44 Suppl 1:590.
6
Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Singapore Med J. 1998 Aug;39(8):357-8.
7
Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.异环磷酰胺/美司钠24小时输注治疗小细胞肺癌的经验。
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S29. doi: 10.1007/BF00647447.
8
[Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].[丝裂霉素C/异环磷酰胺与丝裂霉素C/长春地辛及顺铂/依托泊苷用于晚期非小细胞支气管癌化疗的前瞻性随机研究]
Pneumologie. 1990 Feb;44 Suppl 1:258-60.
9
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.依托泊苷在小细胞肺癌患者中的药代动力学与生存情况:一项多中心研究
Lung Cancer. 2008 Nov;62(2):261-72. doi: 10.1016/j.lungcan.2008.03.008. Epub 2008 Apr 28.
10
A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer.
Semin Oncol. 1994 Jun;21(3 Suppl 4):28-33.